Pfizer pushes deeper into China with stake in cancer biotech
Bio Pharma Dive
SEPTEMBER 30, 2020
The $200 million investment in CStone Pharmaceuticals puts Pfizer in charge of selling a cancer immunotherapy in the world's second largest drug market.
Sat.Sep 26, 2020 - Fri.Oct 02, 2020
358 
Half a million-dollar bonus for cancer drug price increase
World of DTC Marketing
OCTOBER 1, 2020
WHAT NOW: The idea that most pharma companies are here to serve patients is a canard. Pharma CEO’s serve themselves with big salaries tied to drug prices and keeping drugs from coming off patent. On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee. While at the company, Alles saw a massive increase in the price of the cancer drug Revlimid — and Porter broke down just what it got Alles in return.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Novacyt signs deal with UK government for COVID-19 testing kits
Pharma Times
SEPTEMBER 29, 2020
First phase will see company deploy 300 PCR instruments to the UK
Italy and India the only pharma economies to improve score in 2020 according to the CPhI Pharma Index
Pharma Mirror
SEPTEMBER 29, 2020
Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index shows only Italy and India have improved their score in 2020, with the majority of industry executives looking for new supply chain partners. The Index – an aggregated confidence score across the five. The post Italy and India the only pharma economies to improve score in 2020 according to the CPhI Pharma Index appeared first on Pharma Mirror Magazine.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Biogen's all-important Alzheimer's drug enters the review gauntlet
Bio Pharma Dive
SEPTEMBER 29, 2020
On Nov. 6, aducanumab will go before a panel of experts who will review it and make recommendations to the FDA. Meanwhile, the drug has also caught the attention of a powerful cost watchdog group.
Launching a new drug: How much to spend on DTC?
World of DTC Marketing
SEPTEMBER 30, 2020
HERE”S THE DEAL: Determining how much to spend for the launch of a new drug is a challenge we all face and you have to be ready to shift funds from channels that are failing to provide the lift in brand awareness to channels that hit the bullseye on your objectives. The biggest request we get from clients is guiding them through the process of allocating total DTC spend along with channel allocation.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
FDA launches Digital Health Center of Excellence
pharmaphorum
SEPTEMBER 28, 2020
The FDA has launched its Digital Health Center of Excellence (DHCoE), as the agency continues with its commitment to advancing use of technology such as mobile health devices, software and wearables to create medical products. Housed within the agency’s Center for Devices and Radiological Health, the DHCoE is part of a wider strategy to encourage development of digital health products and therapeutics.
5 FDA approval decisions to watch in the 4th quarter
Bio Pharma Dive
SEPTEMBER 29, 2020
The world's attention will be on the FDA as it considers initial data from coronavirus vaccine developers. But several other important drugs, including a CAR-T therapy and an Ebola antibody, will also be on the agency's agenda.
Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection
XTalks
SEPTEMBER 30, 2020
While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. Two recent studies have shown that individuals who lack an important immune factor may have reduced ability to fight the virus. The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefell
Accenture reveals data science project for paediatric leukaemia
Pharma Times
SEPTEMBER 28, 2020
Insights from project could potentially improve precision medicine use for paediatric AML
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Regeneron’s antibody cocktail active against coronavirus, cuts symptoms
pharmaphorum
SEPTEMBER 30, 2020
Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. The ongoing double-blind trial measures the effect of adding REGN-COV2 to usual standard of care, compared with usual standard of care.
Merck research chief Roger Perlmutter to retire, leaving immunotherapy legacy
Bio Pharma Dive
OCTOBER 2, 2020
Under his leadership, Merck developed a once overlooked cancer drug into Keytruda, now a top-selling medicine and foundational treatment for more than a dozen types of tumors.
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study
BioPharma Reporter
SEPTEMBER 28, 2020
Ena Respiratoryâs preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
NeuroRx and Relief Therapeutics sign new supply agreements for COVID-19 drug
Pharma Times
SEPTEMBER 30, 2020
Supply chain agreements come before upcoming data readout
Careology teams up with private GP group on COVID-19 monitor
pharmaphorum
OCTOBER 1, 2020
A digital tool that allows doctors to monitor patients with COVID-19 remotely in real time and intervene when treatment is needed has been launched in the UK. The mobile app – developed by digital heath specialist Careology – provides advice on COVID-19 symptoms and links patients with doctors at the London General Practice, a private GP group with around 50,000 people on its books, via online video consultations.
Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge
Bio Pharma Dive
OCTOBER 1, 2020
An 18-month investigation by the House Oversight Committee targeted the pricing practices behind the top-selling drugs Revlimid and Copaxone.
CRISPR Technology Edges Closer to Commercial Use
BioSpace
SEPTEMBER 30, 2020
While CRISPR has been used as a research tool for the most part, the technology is moving toward commercial applications.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
The new pharma collaborations driving transformative research in oncology
pharmaphorum
SEPTEMBER 29, 2020
The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology. As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.
Regeneron says antibody drug may speed recovery of patients with mild COVID-19
Bio Pharma Dive
SEPTEMBER 29, 2020
Preliminary study data suggest the treatment could help people whose bodies aren't already fighting off infection, a finding the biotech is discussing with regulators.
Syntegon goes live at PACK EXPO Connects 2020
Pharma Mirror
OCTOBER 1, 2020
Since the in-person PACK EXPO International and Healthcare Packaging EXPO have been cancelled, the process and packaging technology specialist Syntegon is presenting its latest solutions at the virtually-hosted PACK EXPO Connects from November 9 to 13, 2020. In a series of video and Q&A sessions, Syntegon is showcasing its intelligent and sustainable technologies for the.
Novel nasal spray reduces COVID-19 viral replication in animal study
Pharma Times
SEPTEMBER 29, 2020
Treatment is being developed by Australian biotech Ena Respiratory
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Chatbots: Designing the Human Side of the Experience (Pt. One)
Intouch Solutions
OCTOBER 1, 2020
Robots are no longer the stuff of science fiction, and as more brands adopt conversational AI, some key considerations can enhance the chatbot user experience. In part one of this two-part series, we’ll talk about chatbots, human users, and live agents, and offer several tips for success. The post Pharma Chatbots: Designing the Human Side of the Experience (Pt.
After setback in the US, Galapagos' main drug finds success elsewhere
Bio Pharma Dive
SEPTEMBER 28, 2020
A month after the FDA surprisingly rejected the rheumatoid arthritis drug, known as filgotinib, and more recently, Jyseleca, it's been cleared by regulators in Europe and Japan.
6 Reasons Why Ranitidine Is Harmful and How It Caused Cancer to Many
Pharma Mirror
OCTOBER 1, 2020
Ranitidine is a pharmaceutical drug that is categorized as a histamine antagonist, also called an H2 blocker, that has popularly been used to treat acid reflux. However, this medication had recently raised controversies when the Food and Drug Administration (FDA) announced a product recall of this drug from the market due to the presence of. The post 6 Reasons Why Ranitidine Is Harmful and How It Caused Cancer to Many appeared first on Pharma Mirror Magazine.
NHS England report identifies need for ‘radical change’ in diagnostic services
Pharma Times
OCTOBER 2, 2020
Diagnostics: Recovery and Renewal report identifies a number of key actions
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Biopharma Update on the Novel Coronavirus: September 28
BioSpace
SEPTEMBER 27, 2020
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
FDA delays testing of Inovio's coronavirus vaccine
Bio Pharma Dive
SEPTEMBER 28, 2020
The FDA has suspended the planned start of a late-stage trial of Inovio's experimental shot, dealing another setback to one of the most advanced DNA-based vaccine programs in development.
Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay
Pharma Mirror
OCTOBER 1, 2020
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular and fully automated diagnostics platform Idylla™.
Pfizer scores a speedy review in the US for Duchenne gene therapy
Pharma Times
OCTOBER 2, 2020
Fast track designation is based on promising phase Ib results
Let's personalize your content